Do Analysts Think Protalix BioTherapeutics Inc (PLX) Is Still Worth Buying In 2025?

Protalix BioTherapeutics Inc (AMEX:PLX) does about 908.84K shares in volume on a normal day but saw 12690476 shares change hands in the recent trading day. The company now has a market cap of 122.59M USD. Its current market price is $1.54, marking an increase of 6.21% compared to the previous close of $1.45. The 52 week high reached by this stock is $3.10 whilst the lowest price level in 52 weeks is $0.82.

The consensus objective for the share price is $15.00, suggesting that the stock has a potential upside of 89.73% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 08, 2020 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $3 and $11. Rodman & Renshaw initiated its price target at $3.50.

The current price level is 2.56%, -21.68%, and -17.93% away from its SMA20, SMA50, and SMA200 respectively, with the PLX price moving above the 50-day SMA on current market day. Protalix BioTherapeutics Inc (PLX) stock is up 10.00% over the week and -3.14% over the past month. Its price is 19.38% year-to-date and -18.09% over the past year.

To reach the target analysts have set, the stock logically needs to grow 89.73 percent from here.

The company has a return on investment of 7.97% and return on equity of 10.42%. The price to earnings ratio (P/E ratio) amounts to 36.67 while the forward price to earnings ratio is 3.42. The beta has a value of -0.23. Price to book ratio is 2.66 and price to sales ratio is 2.05.

Comet Reports
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.